REG - Abingdon Health PLC - $2.5m Contract for clinical self-test development

Abingdon HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260312:nRSL3087Wa&default-theme=true

RNS Number : 3087W  Abingdon Health PLC  12 March 2026

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

$2.5m Contract Award for development of clinical self-test

 

York, U.K. 12 March 2026: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and regulatory services provider for
rapid diagnostic tests and med-tech, announces that it has been awarded a
significant contract with an expected value of approximately US$2.5 million to
provide project management and expert technical support for the development
and regulatory submission of a clinical self-test.

 

The Company has signed a Services Agreement with this UK-based customer to be
delivered in phases over an 18-month period via orders under the Services
Agreement. The project represents a strategically important contract in the
clinical self-test diagnostics sector and demonstrates Abingdon Health's
expertise in managing complex, multi-stakeholder international diagnostic
programmes. The contract will commence shortly with the majority of the
revenues to be recognised in the financial year ending 30 June 2027.

 

Abingdon Health will provide end-to-end project management and technical
support across three key phases: Feasibility, Design & Development and
Verification & Validation. The work leverages the Company's established
capabilities in lateral flow test development, clinical diagnostics, ISO
13485:2016 quality management systems, and regulatory pathways.

 

This contract award underscores Abingdon Health's position as a leading
provider of integrated CDMO/CRO services for rapid diagnostic tests.

 

Dr Chris Hand, Executive Chairman, commented: "We are delighted to have been
selected and to be working with this client on this important global health
project. Our multidisciplinary in-house immunodiagnostics specialists,
regulatory experts, and programme managers are ideally suited to deliver this
complex international programme. This award reinforces our strategic position
in the point-of-contact diagnostics market and demonstrates the value of our
CDMO/CRO platform to major international organisations."

 

Enquiries:

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                     Via Walbrook PR
 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format.  Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK. Its consultancy services range from design, implementation and maintenance
of quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.
 The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing
and performance evaluation to generate the required technical and data for
regulatory approval for lateral flow and other in vitro diagnostic assays from
its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGPUMCWUPQGBG



            Copyright 2019 Regulatory News Service, all rights reserved